ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 23

Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies

Kelly Wise1, Dustin Lewis2, Bethanne Thomas2, Karla Jones3, Stephanie Lemle2, Darby MacDonald2, Fatima Barbar-Smiley2, Vidya Sivaraman2 and Cagri Yildirim-Toruner3, 1Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Rheumatology, Nationwide Children's Hospital, Columbus, OH

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Compliance, juvenile idiopathic arthritis (JIA), medication, pharmacists and quality improvement

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Title: Quality, Health Services and Education Research Poster Breakout I

Session Type: Abstract Submissions

Session Time: 4:45PM-5:15PM

Background/Purpose:  Biologic therapies have become a standard of care for many pediatric rheumatic diseases such as juvenile idiopathic arthritis (JIA) and periodic fever syndromes.  Biologics, including adalimumab, etanercept, canakinumab, and tocilizumab, are categorized as specialty medications. Specialty medications are generally defined by the following: use in the treatment of complex chronic conditions, high cost (typically >$600 per month), usually requiring special storage, handling, and site-of-care administration, and involving a significant degree of patient education, monitoring, and management. Barriers that can prevent patients from obtaining specialty medications include need for prior authorizations, high copayments, directing prescriptions to the preferred specialty pharmacies, and coordinating delivery of medications from the specialty pharmacy. Pharmacists can be used in the ambulatory setting to aid in procurement and management of specialty medications. Nationwide Children’s Hospital (NCH) has instituted a specialty pharmacy for the division of rheumatology to aid in prior authorization, injection teaching, and medication management of select biologic therapies. This is expected to result in increased adherence to treatment and achievement of inactive disease. The primary aim of this pilot study is to assess the medication possession ratio (MPR) for individuals on adalimumab, etanercept, canakinumab, and tocilizumab that were enrolled in NCH Specialty Pharmacy for an index period of October 2016 to January 2017.

Methods:  A retrospective review of prescriptions filled at NCH Specialty Pharmacy over a 4 month period assessed overall number of prescriptions, number of specialty prescriptions, patients enrolled, and MPR for adalimumab, etanercept, canakinumab, and tocilizumab. MPR was calculated for patients with >1 fills at NCH Specialty Pharmacy. An MPR of 1 reflects 100% adherence.

Results:  In the first four months, NCH Specialty Pharmacy filled a total of 446 prescriptions and 132 specialty medications (adalimumab n=55; etanercept n=37; canakinumab n=19; tocilizumab n=11; other n=10) for 46 rheumatology patients. Average and median MPRs were assessed for adalimumab (0.95, 1) etanercept (0.95, 1), canakinumab (0.99, 1), and tocilizumab (1, 1), respectively. Overall, the average MPR was 0.96 and median MPR was 1.

Conclusion:   The implementation of an institutional specialty pharmacy has added services to improve outcomes for children with rheumatic diseases. NCH was able to ensure a median MPR of 1 for all biologics filled at NCH Specialty Pharmacy during the pilot phase. It is expected that improvement in medication adherence will result in achievement of inactive disease. Strategies used by NCH Specialty Pharmacy to maintain an MPR of 1 include coordination of prior authorization, injection teaching by a pharmacist, and medication management consisting of monthly follow up with the patient or caregiver to schedule medication delivery. Rheumatologists at NCH will continue to enroll patients with JIA and other autoinflammatory diseases in NCH Specialty Pharmacy to ensure streamlined care and improved patient outcomes.


Disclosure: K. Wise, None; D. Lewis, None; B. Thomas, None; K. Jones, None; S. Lemle, None; D. MacDonald, None; F. Barbar-Smiley, None; V. Sivaraman, None; C. Yildirim-Toruner, None.

To cite this abstract in AMA style:

Wise K, Lewis D, Thomas B, Jones K, Lemle S, MacDonald D, Barbar-Smiley F, Sivaraman V, Yildirim-Toruner C. Impact of an Institutional Specialty Pharmacy on Adherence to Biologic Therapies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/impact-of-an-institutional-specialty-pharmacy-on-adherence-to-biologic-therapies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-an-institutional-specialty-pharmacy-on-adherence-to-biologic-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology